Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data

by Thanos Panagiotidis | Apr 29, 2020 | Drug Discovery Applications, Publications and presentations

Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data Preprint Paper. Abstract Contemporary deep learning approaches still struggle to bring a useful improvement in the field of drug discovery due to the challenges of sparse, noisy and...
Practical Applications of Deep Learning to Imputation of Drug Discovery Data Video

Practical Applications of Deep Learning to Imputation of Drug Discovery Data Video

by Thanos Panagiotidis | Apr 29, 2020 | Cerella, Presentations and Webinars, Videos

Practical Applications of Deep Learning to Imputation of Drug Discovery Data Video Held on 28 April 2020. This webinar was presented by our guest Julian Levell (Constellation Pharmaceuticals) and Ben Irwin (Optibrium). We discussed limitations of pharmaceutical data...
Predicting Reactivity to Drug Metabolism: Beyond P450s – Modelling FMOs and UGTs Video

Predicting Reactivity to Drug Metabolism: Beyond P450s – Modelling FMOs and UGTs Video

by Thanos Panagiotidis | Apr 1, 2020 | Presentations and Webinars, Videos

Predicting Reactivity to Drug Metabolism: Beyond P450s – Modelling FMOs and UGTs Video Held on 31 March 2020. After the success of the current P450 models it is time to introduce additional enzyme systems to StarDrop and include enzymes from both modification and...

Optibrium and Intellegens achieve further success in Open Source Malaria initiative with in vitro validation of in silico generated compound

by Thanos Panagiotidis | Apr 1, 2020 | News

CAMBRIDGE, UK, 01 April, 2020 – Optibrium™, leading providers of software and services for drug discovery, and Intellegens™, a spin-out from the University of Cambridge with a unique Artificial Intelligence (AI) toolset, today announced they have reached a further...

Recent Posts

  • Optibrium appoints Steve Yemm as Chief Commercial Officer
  • Introduction to StarDrop™
  • Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
  • Inspyra™– Introduction
  • Cerella™– Introduction

Archives

Categories

  • Asteris
  • Cerella
  • Downloads
  • Drug Discovery Applications
  • Events
  • Example Code
  • General
  • In Silico Modelling
  • Latest Videos
  • Models
  • Multi-Parameter Optimisation
  • News
  • Ocura
  • Pipeline Pilot Protocols
  • Presentations and Webinars
  • Publications and presentations
  • Scoring Profiles
  • Scripts/Addons
  • StarDrop Hints and Tips
  • StarDrop Modules and Features
  • StarDrop Tutorials
  • Tutorials
  • Upcoming webinar
  • Videos
  • Webinars

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

The Optibrium team works at the forefront of decision-analysis and predictive modelling research, developing innovative products that enhance the efficiency and productivity of drug discovery.

enquiries & support

General: [email protected]
StarDrop: [email protected]
Cerella: [email protected]
Press: [email protected]
Vacancies: [email protected]

  • Follow
  • Follow
further information

View our Privacy Policy

Copyright © 2023 Optibrium, Ltd. All Rights Reserved.
Optibrium™, StarDrop™, Augmented Chemistry®, Cerella™, Asteris™, Ocura™, Glowing Molecule™, WhichP450™, Auto-Modeller™, Nova™, MPO Explorer™ and Card View® are trademarks of Optibrium Ltd. Augmented Chemistry® is registered only in the UK and EU. Card View® is registered only in the United States. Matsy™ is a trademark of NextMove Software Ltd., BIOSTER™ is a trademark of iKem Szolgáltató és Kereskedelmi BT, Derek Nexus™ is a trademark of Lhasa Ltd., Surflex eSim3D is a trademark of BioPharmics LLC, and SeeSAR™ is a trademark of BioSolveIT GmbH. US Patent Numbers 9,224,098 and 9,367,812

Website designed and developed by Identity Creative.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}